<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146350</url>
  </required_header>
  <id_info>
    <org_study_id>AM1901D3</org_study_id>
    <nct_id>NCT04146350</nct_id>
  </id_info>
  <brief_title>A Prospective Multicenter Study of Different Surgical Methods in the Treatment of High Myopic Macular Schisis</brief_title>
  <acronym>Recovery</acronym>
  <official_title>A Prospective Multicenter Study of Different Surgical Methods for the Treatment of Macular Schisis in High Myopia Based on the Real World</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aier School of Ophthalmology, Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aier School of Ophthalmology, Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In view of the current problem of treating high myopic macular schisis, the main purpose of
      our study is to find out the most appropriate time of surgical intervention, to compare the
      effectiveness and safety of various surgical methods in the treatment of high myopic macular
      schisis, and to find out the advantages and disadvantages of each surgical method in the
      treatment of MF. As well as the outcomes and complications of long-term follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Anticipated">June 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>foveal thickness</measure>
    <time_frame>change from baseline foveal thickness at 3, 6, 9, 12 months</time_frame>
    <description>measured by OCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>retinal thickness of the most significant schisis</measure>
    <time_frame>change from baseline at 3, 6, 9, 12 months</time_frame>
    <description>measured by OCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>best corrected visual acuity</measure>
    <time_frame>change from baseline at 3, 6, 9, 12 months</time_frame>
    <description>BCVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mf-ERG</measure>
    <time_frame>change from baseline at 3, 6, 9, 12 months</time_frame>
    <description>multifocal-ERG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual quality questionnaire</measure>
    <time_frame>change from baseline at 3, 6, 9, 12 months</time_frame>
    <description>Visual quality questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>axial length</measure>
    <time_frame>change from baseline at 3, 6, 9, 12 months</time_frame>
    <description>axial length measured by IOL Master</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Macular Schisis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PPV+/-Cat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PPV+/-Cat+Gas</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PPV+ILM+/-Cat+/-Gas</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PPV+ILM+/-Cat+/-Oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PSR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gas</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PPV+/-Cat</intervention_name>
    <description>pars plana vitrectomy+/-cataract</description>
    <arm_group_label>PPV+/-Cat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PPV+/-Cat+Gas</intervention_name>
    <description>pars plana vitrectomy+/-cataract+gas tamponade</description>
    <arm_group_label>PPV+/-Cat+Gas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PPV+ILM+/-Cat+/-Gas</intervention_name>
    <description>pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-gas tamponade</description>
    <arm_group_label>PPV+ILM+/-Cat+/-Gas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PPV+ILM+/-Cat+/-Oil</intervention_name>
    <description>pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade</description>
    <arm_group_label>PPV+ILM+/-Cat+/-Oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PSR</intervention_name>
    <description>posterior scleral reinforcement</description>
    <arm_group_label>PSR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）</intervention_name>
    <description>posterior scleral reinforcement+pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade (or gas)</description>
    <arm_group_label>PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gas</intervention_name>
    <description>gas tamponade alone</description>
    <arm_group_label>Gas</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diopter ≤-6.00D or axial length ≥ 26.00mm;

          2. OCT showed macular schisis with or without macular retinal detachment;

          3. agreed to participate in this project and signed informed consent form.

        Exclusion Criteria:

          1. OCT confirmed full-thickness macular hole with or without macular retinal detachment；

          2. submacular active or inactive CNV;

          3. previous vitreoretinal surgery and anti-glaucoma surgery；

          4. with rhegmatogenous retinal detachment, ocular trauma, glaucoma, corneal opacity and
             other ophthalmic diseases;

          5. complicated with severe systemic disease can not tolerate surgery or follow-up;

          6. do not agree to participate the project or disagree with the follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weisheng Li</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Aier Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiasong Yang</last_name>
    <phone>+8618113024536</phone>
    <email>cammel@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wensheng Li</last_name>
    <phone>+8618650424985</phone>
    <email>drlws@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Aier Eye Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiasong Yang</last_name>
      <phone>+8618113024536</phone>
      <email>cammel@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Wensheng Li</last_name>
      <phone>+8618650424985</phone>
      <email>drlws@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Dolar-Szczasny J, Święch-Zubilewicz A, Mackiewicz J. A Review of Current Myopic Foveoschisis Management Strategies. Semin Ophthalmol. 2019;34(3):146-156. doi: 10.1080/08820538.2019.1610180. Epub 2019 May 6.</citation>
    <PMID>31060414</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

